Aigen Investment Management LP acquired a new position in Sanofi (NASDAQ:SNY – Get Rating) in the third quarter, HoldingsChannel.com reports. The fund acquired 64,773 shares of the company's stock, valued at approximately $2,463,000.
A number of other large investors have also modified their holdings of SNY. FMR LLC raised its position in shares of Sanofi by 1.3% during the 2nd quarter. FMR LLC now owns 18,715,053 shares of the company's stock worth $936,314,000 after purchasing an additional 234,158 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Sanofi by 162.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 17,244,354 shares of the company's stock worth $862,735,000 after purchasing an additional 10,684,509 shares during the last quarter. Invesco Ltd. raised its position in shares of Sanofi by 2.3% during the 1st quarter. Invesco Ltd. now owns 5,077,848 shares of the company's stock worth $260,697,000 after purchasing an additional 112,404 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Sanofi by 276.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company's stock worth $172,611,000 after purchasing an additional 2,468,271 shares during the last quarter. Finally, Lazard Asset Management LLC raised its position in shares of Sanofi by 0.8% during the 1st quarter. Lazard Asset Management LLC now owns 3,321,721 shares of the company's stock worth $170,536,000 after purchasing an additional 25,457 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company's stock.
Get Sanofi alerts:Sanofi Stock Performance
Sanofi stock opened at $45.86 on Tuesday. The firm has a 50 day simple moving average of $47.91 and a 200-day simple moving average of $43.28. Sanofi has a 1-year low of $36.91 and a 1-year high of $58.10. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.29 and a quick ratio of 0.34. The stock has a market cap of $115.64 billion, a price-to-earnings ratio of 16.21, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56.
Analysts Set New Price Targets
SNY has been the subject of several research analyst reports. Morgan Stanley restated an "overweight" rating on shares of Sanofi in a research report on Tuesday, December 13th. TheStreet upgraded shares of Sanofi from a "c+" rating to a "b-" rating in a report on Friday, December 2nd. StockNews.com started coverage on shares of Sanofi in a report on Wednesday, October 12th. They issued a "strong-buy" rating for the company. Barclays cut their price objective on shares of Sanofi from €105.00 ($112.90) to €85.00 ($91.40) and set an "equal weight" rating for the company in a report on Friday, October 14th. Finally, The Goldman Sachs Group started coverage on shares of Sanofi in a report on Friday, December 16th. They issued a "buy" rating for the company. Five analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $102.88.About Sanofi
(Get Rating)
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities.
Further Reading
- Get a free copy of the StockNews.com research report on Sanofi (SNY)
- Why Is Wall Street Loving Amazon So Much?
- Want to Invest in ChatGPT? Then Buy Microsoft Stock
- Anhui Conch: Opportunity With Cement Solid Cash Flows
- Is Merck Stock a Buy After Its Post-Earnings Sell-Off?
- Is Biotech Immunocore About To Make A 25% Price Move?
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Get Rating).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.